This journal activity provides practitioners with the knowledge needed to treat oligometastatic cancer.

This journal activity provides practitioners with the knowledge needed to appropriate counsel and educate patients requiring chemoradiotherapy for esophageal cancer and provide practitioners with the knowledge regarding common late effects of treatment in this patient population.

This journal activity provides practitioners with the knowledge needed to aid in identifying which patients may benefit from brain metastasis-directed radiation therapy. Understanding these factors may help patients and their families clarify their goals of care.

This journal activity provides practitioners with essential technological context for FLASH-RT clinical trial QC considerations, including review of critical reportable parameters, novel dosimetry challenges, and implications for future system- and protocol-specific credentialing.

This journal activity provides practitioners with the knowledge needed to identify the role of radiation therapy in vaginal brachytherapy.

This journal activity provides practitioners with a comprehensive review of the data to date, as well as expert opinions, on the incorporation of genomic classifiers into prostate cancer risk stratification in clinical practice as well as future translational directions.

This journal activity provides radiation oncology training programs and interview committees with the knowledge needed to implement holistic review of residency applicants, including the use of standardized interview content and scoring rubrics.

This journal activity provides practitioners with the knowledge to guide treatment of NSCLC.

This journal activity provides practitioners with an evidence-based summary of barriers to diversity in clinical trials and approaches to increase diversity that are specific to radiation oncology.

This journal activity provides practitioners with the knowledge for practice improvement in treating patients with non-small cell lung cancer undergoing definitive chemoradiation followed by consolidative durvalumab.